GPCR
Structure Therapeutics Inc - Phase 1 Study of Accg-2671 Expected to Start by Year End 2025
时间：2024-12-18 05:01:00 市场： 美股 综合
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity
时间：2024-12-18 05:01:00 市场： 美股 综合
Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.d., Ph.d. to Chief Medical Officer and Appointment of Ashley Hall, J.d. as Chief Development Officer
时间：2024-09-18 04:05:00 市场： 综合 美股